NEW YORK, May 23, 2017 /PRNewswire/ --
Today, Stock-Callers.com reviews the following Medical Appliances and Equipmentcompanies: Corindus Vascular Robotics Inc. (NYSE MKT: CVRS), InspireMD Inc. (NYSE MKT: NSPR), Xtant Medical Holdings Inc. (NYSE MKT: XTNT), and Second Sight Medical Products Inc. (NASDAQ: EYES). These stocks are part of the Healthcare sector, which is
Corindus Vascular Robotics
On Monday, shares in Waltham, Massachusetts headquartered Corindus Vascular Robotics Inc. recorded a trading volume of 290,675 shares. The stock ended the session 4.42% higher at $1.18. The Company's shares have surged 88.80% over the previous three months and 68.96% on an YTD basis. The stock is trading 20.14% above its 200-day moving average. Moreover, shares of the Company, which designs, manufactures, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures, have a Relative Strength Index (RSI) of 47.99.
On May 17th, 2017, Corindus Vascular Robotics announced that it plans to participate in the 18th Annual Investor Conference hosted by B. Riley Co. in Santa Monica, CA. Management is scheduled to present on May 24th, 2017, at 9:30 a.m. PT. The live, audio webcast may be accessed on the Company's website. The free research report on CVRS is available at:
Tel Aviv, Israel headquartered InspireMD Inc.'s stock closed the day 0.27% higher at $0.56 with a total trading volume of 66,310 shares. The Company's shares are trading 28.03% below their 50-day moving average. Shares of the Company, which focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases, have an RSI of 32.01.
On May 18th, 2017, InspireMD announced that the team of Prof. Alberto Cremonesi, Chief of the Cardiovascular Department and Director of the Interventional Cardiovascular Unit of Maria Cecilia Hospital - GVM Care & Research, Cotignola, performed a live, stent endovascular interventional procedure featuring the CGuard™ EPS Carotid Stent at EuroPCR 2017. The case was transmitted real time to the entire congress. Dr. Cremonesi is one of the Course Directors of EuroPCR. The complimentary report on NSPR can be downloaded at:
Shares in Belgrade, Montana headquartered Xtant Medical Holdings Inc. recorded a trading volume of 236,954 shares. The stock ended yesterday's trading session 0.56% higher at $0.45. The Company's shares have advanced 7.14% in the previous three months. The stock is trading below its 50-day moving average by 16.38%. Furthermore, shares of Xtant Medical, which develops, manufactures, and markets regenerative medicine products and devices in the US and internationally, have an RSI of 43.89.
On May 16th, 2017, Xtant Medical announced that it has entered into a licensing agreement with Sites Medical LLC for utilization of their proprietary OsteoSync™ Ti technology, a best-in-class porous titanium scaffold. Utilizing Q2 Metrics data, the Company estimates the total addressable US market for its technologies that can utilize OsteoSync Ti at $2.5 billion with a five-year CAGR approaching 4.75%. Visit us today and download our complete research report on XTNT for free at:
Second Sight Medical Products
Sylmar, California headquartered Second Sight Medical Products Inc.'s stock finished Monday's session flat at $1.14 with a total trading volume of 210,662 shares. The Company's shares have advanced 1.79% in the last one month. The stock is trading below its 50-day moving average by 5.24%. Additionally, shares of the Company, which develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the US, Italy, Germany, France, and Canada, have an RSI of 44.42.
On May 17th, 2017, Second Sight Medical Products announced that Will McGuire, President and CEO, will present at the 18th Annual B. Riley Institutional Investor Conference on May 25th, 2017, at 9:30 a.m. PT at the Arcadia D, Loews Santa Monica Beach Hotel. The presentation will be webcast. Get free access to your technical report on EYES at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All